Skip to content
Thomas Ciulla MD PC
  • Blog Homepage
  • Return to Main Site
April 11, 2020

How are medical therapies valued?

Just published this article on cost effectiveness analysis…

Cost Effectiveness Analysis in Retina. New Onetime Treatments Require New Reimbursement Models


Diabetic retinopathy is a leading cause of vision loss.
Luxturna serves as a model for other gene therapy candidates

Copyright © 2017 | Terms of Use | Privacy Policy
NOTICE: Individual surgical results may vary. Patients should discuss with their physician whether surgery is right for them and the risks involved. Click here for more information.
  • Kale by LyraThemes.com.